**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 29977**

**Manuscript Type: REVIEW**

**Intraepithelial lymphocytes, scores, mimickers, and challenges in diagnosing gluten-sensitive enteropathy (Celiac disease)**

Sergi C *et al.* Diagnosing gluten-sensitive enteropathy

Consolato Sergi, Fan Shen, Gerd Bouma

**Consolato Sergi,** TianYou Hospital, Wuhan University of Science and Technology, Wuhan 430081, Hubei Province, China

**Consolato Sergi,** Departments of Laboratory Medicine and Pathology, University of Alberta, Edmonton AB T6G 2R3, Canada

**Fan Shen,** Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton AB T6G 2R3, Canada

**Gerd Bouma,** Department of Gastroenterology and Hepatology, Vrije Universiteit Medical Center, 1081 HV Amsterdam, The Netherlands

**Author contributions:** All authors contributed to the manuscript.

**Conflict-of-interest** **statement:** No potential conflicts of interest relevant to this article were reported.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Consolato Sergi, MSc, MD, PhD, FRCPC, Professor,** Departments of Laboratory Medicine and Pathology, 116 St and 85 Ave, University of Alberta, Edmonton AB T6G 2R3, Canada. sergi@ualberta.ca

**Telephone:** + 31-20-4440613

**Fax**: +31-20-4440554

**Received:** September 1, 2016

**Peer-review started:** September 2, 2016

**First decision:** September 21, 2016

**Revised:** October 27, 2016

**Accepted:** December 16, 2016

**Article in press:**

**Published online:**

**Abstract**

The upper digestive tract is routinely scoped for several causes of malabsorption and the number of duodenal biopsy specimens has increased notably in the last 10 years. Gluten-sensitive enteropathy (GSE) is an autoimmune disease, which shows an increase in prevalence worldwide and requires a joint clinico-pathological approach. The classical histopathology of GSE with partial or total villous blunting is well recognized, but the classification of GSE is not straightforward. Moreover, several mimickers of GSE with intraepithelial lymphocytosis have been identified in the last 20 years with drug interactions and medical comorbidities adding to the conundrum. In this review, we report on the normal duodenal mucosa, the clinical presentation and laboratory diagnosis of GSE, the duodenal intraepithelial lymphocytes and immunophenotype of GSE-associated lymphocytes, the GSE mimickers, the differences “across oceans” among guidelines in diagnosing GSE, and the use of a synoptic report for reporting duodenal biopsies in both children and adults in the 21st century.

**Key words:** Gluten; Duodenum; Lymphocytes

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Striking and unique microphotographs with comparison of classification of GSE across oceans and tables useful for the practice of gastroenterology.

Sergi C, Shen F, Bouma G. Intraepithelial lymphocytes, scores, mimickers, and challenges in diagnosing gluten-sensitive enteropathy (Celiac disease). *World J Gastroenterol* 2016; In press

**INTRODUCTION**

In the last decade, there have been a plethora of publications in refining several gastrointestinal diseases. It has emerged as a period of an unceasing interest, particularly for diseases of the upper gastrointestinal tract[1-14]. In the hands of physicians reading histopathology reports, the number of duodenal biopsies with normal or near normal villous architecture and increased intraepithelial lymphocytes (IELs) appears to be collectively growing. Increased IELs or intraepithelial lymphocytosis (IEL) in an otherwise apparently normal villous architecture can be a puzzle for both pathologists and treating physicians and may raise several differential diagnoses[15]. Moreover, the histopathology report may not be useful as it is, if it is not complemented with clinical and laboratory information. The report may be unsatisfactory due to lack of knowledge, incomplete performance of special stains or inadequate application of technical or professional skills. One or more of these issues may contribute to miscommunication between pathologists and clinical colleagues. At first glance, gluten-sensitive enteropathy (GSE) or celiac disease seems to be straightforward, but it is not either from the clinical or the pathologic point of view. There are mysteries behind this disease. Both the pathology and the pathogenesis is not yet fully unveiled. A few years ago, the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) issued some guidelines on GSE defining it as an “immune-mediated systemic disorder, elicited by gluten and related prolamins in genetically susceptible individuals”[16]. GSE has been first described around 200 AD and is known in some countries as “sprue” recalling the 18th century old Samuel Gee’s work “*On the Coeliac Affection*”[17]. To date, genetic studies have identified 43 predisposing loci that collectively explain some 50% of the genetic variance in GSE, but more than 90% of GSE-associated single nucleotide polymorphisms (SNPs) localize to the non-coding genome[18-20]. There is indeed a large epigenomic component that may play a contributive role and a better understanding of the genomic-epigenomic relationship may be needed to translate genetic knowledge into future clinical practice[21,22]. In the meantime, pathology remains key in the diagnostic procedures and this review is composed of six parts, focusing on (1) the composition of normal duodenal mucosa; (2) the clinical presentation and laboratory diagnosis of GSE; (3) the immunophenotype of GSE-associated lymphocytes; (4) the GSE mimickers; (5) the differences “across oceans” among guidelines for diagnosing GSE; and (6) the use of a synoptic report for reporting duodenal biopsies in both children and adults.

**NORMAL DUODENAL MUCOSA**

The villous character of the small bowel is intrinsically linked to the aim of an organism to increase its absorptive surface area. In the early embryogenesis, the development of the duodenal epithelium takes place from simple endodermal tubules between the 9th and 10th week of gestation, when the epithelium converts to simple columnar epithelium. The epithelium ends its differentiation just 4-5 d before birth[23]. The usual configuration of the duodenal mucosa contains slender structures protruding from the surface with 3-5 times the height of the crypts. The patchiness of the lymphoid nodules or mucosa-associated lymphatic tissue (MALT) needs to be considered in assessing the duodenal histology and can constitute one of the first pitfalls in interpreting a small intestinal biopsy. In our more than 20 years’ experience of reading duodenal biopsies of healthy individuals across ages we can state that only very few lymphocytes can be usually seen among the epithelial cells. However, the IELs may vary during life and possibly in a circadian cycle. The IELs usually do not go over 5-10 per 100 epithelial cells in healthy individuals. The cut-off between pathological and normal has been decreased in the last three decades from 40 to either 20 or 25 lymphocytes per 100 epithelial cells [24]. Between 5-10 and the pathological threshold (20 or 25) there is a gap that is probably inadequately investigated. The unveiled and/or underlying causes of the “near-normal” cases (5-20 IELs/100 epithelial cells) may be intriguing. The presence of scattered normal lymphocytes in the surface epithelium of the duodenum is not well understood, although the prominent role of the duodenum in assessing the epitopes present in the food should be considered. MALT of the gut is, indeed, crucial for the immunology and preservation of the microbiome[1,18,25]. Lymphocytes are recognized in the duodenal surface epithelium, because of some characteristics that allow them to be differentiated from the epithelial cells. Lymphocytes are characterized by their roundness, cell hyperchromasia, high nucleus-to-cytoplasm ratio, and quite constant intercellular distribution. However, the counting may be jeopardized by a number of factors, including the intrinsic and extrinsic conditions of biopsy grasping by the endoscopist, the laboratory processing of the tissue biopsy, and the individual evaluation of the pathologist[26-28]. Processing of a duodenal biopsy may represent a challenge for some laboratories. In fact, tangentially cut villi of appropriate duodenal regions may look like blunted and, thus, these areas should be avoided when an assessment of the villous architecture is crucial. Although criteria of adequacy are variable among authors of excellent reviews[29,30], in our opinion, it is desirable that at least five consecutive, intact villi that are well-oriented in the plane of section are sent for assessment to the pathologist. The conditions of “consecutiveness” and “intactness” are extremely important for the standardization of studies involving duodenal mucosal tissue. The correct orientation of the biopsy before paraffin embedding may be crucial and 3, but preferably 5 consecutive, intact, and well-oriented villi are the minimum to adequately evaluate the villous architecture. In our opinion, if at least 3 villi are not consecutive, the diagnosis may be uncertain.

IELs are usually localized at the base of the surface epithelium in biopsies from healthy individuals. If the IELs are slightly increased in number, they tend to arrange themselves generally throughout the full thickness of the epithelium. Some ancillary studies have been proposed to give an accurate value of the lymphocytosis. The immunohistochemical typing the cells has been suggested as ancillary technique, but the normal upper limit has been suggested to be set higher than normal, at 29 IELs instead of 25 (or 24 instead of 20) per 100 epithelial cells[31]. The rationale for it is not fully clear, but values between 26 and 29 CD3-positive IELs may be empirically stated as borderline IEL. The term IEL should be reserved when IELs are equal to 30 or superior to this value. Duodenal portions may be different in the number of IELs present and this may also vary according to the ingested food. Duodenal bulb biopsies may show more IELs than distal portions and the other portions of the small bowel are also quite different from duodenum. In fact, villi of the distal bowel tend to be slightly taller apart from areas overlying lymphoid aggregates where they acquire broad based or flat shape. Underneath of the surface epithelium, the lamina propria of the small bowel contains typically an infiltrate of scattered or mild densely lymphocytes, plasma cells, and eosinophils, which constitute the usual complement of the small bowel wall. The number of these three cell types in the lamina propria varies, but usually they are low in number. All three types can be easily recognized in normal biopsies and highlighted by immunohistochemistry or histochemistry using antibodies against CD3 (lymphocytes), CD138 (plasma cells), and Luna special stain (eosinophils), respectively. The presence of more than occasional plasma cells and more than 30 eosinophils per high power field (ocular 10X and objective × 40) should be considered anomalous[28].

**CLINICAL PRESENTATION AND LABORATORY DIAGNOSIS OF GSE**

GSE is a dysregulation of the genome-epigenome with abnormal reaction of the body to gluten-containing food[2,32-40]. In Figure 1, the plant taxonomy and celiac toxicity are depicted. Gluten is a protein that gives dough the elasticity, which allows it to rise without collapsing while trapping the CO2. It is important to remember that gluten is within wheat, rye and barley, but also in wheat derivatives: bulgar, couscous, mataza, seitan, semolina, triticale, spelt, kamut, einkorn, emmer, and anything with ‘wheat’ in the name (except buckwheat) as well. The presentation of GSE in childhood is quite protean, including abdominal distension, diarrhea, anorexia, weight loss, dermatitis herpetiformis, and irritability. Conversely, the presentation of GSE in adulthood include usually abdominal distension, steatorrhea, edema, and lethargy. Infrequent ways of presentation have been described in the literature[18,19]. In case of a suspicion of GSE, both children and adults are first screened using serologic studies for autoantibodies including IgA anti-tissue transglutaminase (aTTG)[35,41]. IgA anti-endomysial autoantibodies (EMA) have been previously used. IgA anti-tissue transglutaminase (tTG) antibodies is the preferred test worldwide showing a sensitivity of 94% and specificity of 97%[42,43]. Both tests are useful in IgA competent patients. The institution of a gluten-free diet starts the decline of the titers of aTTG. False-negative aTTG results may be seen in patients harboring IgA deficiency, which is detected in 1/10 of the GSE patients and testing of IgG isotype of anti-tTG is mandatory. To date, deamidated gliadin peptide (DGP) seems to have better sensitivity in detecting early-stage GSE as compared to the TTG and EMA and has been proposed to be the first line of investigation in IgA deficient patients (see below for differences among gastroenterological societies)[25,41,44,45]. False-positive results may occur in the setting of patients suffering from inflammatory bowel disease, primary biliary cirrhosis, cardio-vascular disease, autoimmune enteropathy, and other immune-mediated disorders[25,29,41,44,46]. Clinical correlation is paramount. In the absence of supportive histologic or laboratory findings, a strong clinical suspicion should be followed by the evaluation for high-susceptibility alleles of the human leukocyte antigens (HLA), HLA-DQ2 or DQ8, or repeating testing before starting gluten withdrawal[47]. If endoscopy is performed, the gross findings remain quite nonspecific and very subjective according to the experience of the endoscopist[48,49]. It is essential to rely not exclusively on the endoscopy, because up to 43% of pediatric patients harboring GSE may show normal-appearing mucosa[50]. Thus, endoscopy should be almost exclusively associated with biopsy. The histologic examination of duodenal biopsies should be performed by a pathologist with specific skills in reading gastrointestinal biopsies. The routine collection of esophageal and gastric biopsy specimens during upper endoscopy should be considered mandatory, particularly to clarify if gastritis or eosinophilic esophagitis are present.

In 2016, the gold standard for the diagnosis of GSE remains the tissue biopsy obtained at endoscopy. The histology of GSE relies on villous atrophy, IEL with or without enterocyte damage, increased inflammatory cells in the lamina propria, and crypt hyperplasia[50,51]. If we consider the normal upper limit of 20 IELs or 25 IELs per 100 epithelial cells in sections stained with hematoxylin and eosin (H&E), the normal ratio of IELs to epithelial cells is 1:5 or 1:4, respectively[2,31,36,52,53]. The presence of neutrophils is a common finding in the histopathology of GSE[54]. Neutrophilic infiltration of the lamina propria may occur in up to 1/3 of patients with GSE. Conversely, more rarely neutrophilic infiltration of the surface epithelium is seen. Neutrophilic crypt abscesses are usually not seen in GSE, while are frequently seen in GSE mimickers, such as infection, peptic duodenitis, or autoimmune enteropathy (see below). The sensitivity of crypt hyperplasia may harbor a higher inter-individual variability and may be not obvious in some patients. Enterocyte damage, as defined by increased nuclear size and decreased cytoplasmic volume, and increased inflammation of the lamina propria, including increased numbers of lymphocytes and plasma cells in the lamina propria are neither specific nor sensitive for GSE. These features are usually present in biopsies of different etiology with marked abnormality of the mucosal architecture[54]. Eosinophils are not uncommon in the gastrointestinal tract [28, 55]. Eosinophilic infiltration of the lamina propria may constitute a separate subgroup of GSE and it has been suggested to report clearly their presence only if sheets of eosinophils are seen. There is an association with eosinophils in the small bowel and esophageal mucosa that has been increasingly recognized[28,56-58] and may require individualized assessment and treatment[30,59,60].

The presence of all histologic components makes indeed the diagnosis of GSE certain, but GSE may show only some of these features and some classifications have been proposed. The Oberhuber *et al*[61] modification of the original classification proposed by Marsh and Crowe remains a cornerstone for both pathologists and clinicians. Marsh classification identifies type I as an infiltrative lesion, characterized by IEL and a normal villous architecture of the duodenal mucosa, type II as an hyperplastic lesion, characterized by IEL and crypt hyperplasia and a normal villous architecture, type III as a destructive lesion, characterized by IEL, crypt hyperplasia and villous atrophy, and type IV as a hypoplastic lesion, characterized by a normal IEL count, normal crypt length, and villous atrophy[62,63]. Oberhuber *et al*[61] modified Marsh classification by dividing the type III lesions into three subtypes, including A (*alike* = near normal) or mild villous atrophy, B (*broad villi*) or marked villous atrophy, and C (*complete*) or completely flat mucosa[61,62] (Table 1). Corazza and Villanacci classification proposed to keep type I infiltrative lesion with a setting of an upper limit of 25 IELs per 100 enterocytes[64] (Table 2). The type II hyperplastic lesion is rarely seen, while Oberhuber types IIIA and IIIB are grouped into a single category or grade B1. Corazza-Villanacci’s argument is pointing to the extreme variability between the same pathologist and different pathologists carrying a not minimal kappa divergence. Oberhuber stage IIIC is maintained in the revised classification as grade B2. Marsh-Oberhuber’s type IV hypoplastic lesion may now be considered obsolete. Since the histological changes of GSE may be patchy in nature, a satisfactory number of biopsies need to be taken. It has been suggested at least four distal duodenal biopsies and at least two biopsies of the duodenal bulb should be performed[61,65]. In consideration of the patchiness, mainly in the pediatric age, many institutions advocate for 6-8 distal duodenal biopsies and two biopsies of the duodenal bulb (CS, personal communication).

**IEL-IMMUNOPHENOTYPE**

T-cell receptors (TCRs) and surface co-receptors are used to characterize the immunological phenotype of the IELs. Normal duodenal biopsies should show in about 90% of healthy individuals a population of IELs which are CD3 and CD8 positive and mostly bearing TCRαβ. Conversely, CD4 positive T-lymphocytes are few. In 1/10 of healthy individuals a distinct population of TCRγδ expressing lymphocytes has been recognized[39,66,67]. It is indeed an integrin of the β7 family, precisely CD103, which is responsible for the adhesion of the T-lymphocytes to epithelial cells[68-70]. If frozen tissue is available, immunohistochemical typing for TCRγδ of T lymphocytes can be performed. In GSE, TCRγδ may reach up to 30%[71]. IEL is constituted mainly by CD8-positive CD3-positive lymphocytes representing the most sensitive immunohistochemical features of GSE. From 40 IELs to 25 or 20 IELs per 100 epithelial cells has been a long journey and immunohistochemistry may help, but also lead to over-diagnose GSE[72]. This may be the case in infiltrative-type lesions in an individual patient with suspected GSE where the duodenal biopsy fails to show an abnormal architecture and the IEL count is difficult to perceptively be assessed adequately. Such situation, although uncommon, may be a sign of latent GSE, despite other causes may be at the origin of this finding. To the best of our knowledge, its clinical relevance remains to be adequately assessed by long-term follow-up studies. An increased IEL count in an otherwise normal small bowel biopsy specimen is obviously not specific for GSE and may be associated with numerous conditions such as non-steroidal anti-inflammatory drugs (NSAIDs) use, microorganisms, bacterial overgrowth, immunological disorders, and lymphocytic or collagenous colitis among others. In examining the biopsies of patients with GSE, the number of CD8-positive, CD3-positive T-lymphocytes is in crescendo towards the villous tips, while normal villi or non-GSE lymphocytes show a crescendo towards the base of the villi (*crescendo* versus *decrescendo* pattern) (Figure 2)[9,13,59]. Immunohistochemical investigation for TCRγδ in IEL is as sensitive and specific as the villous tip IEL count and may result in distinguishing other intestinal disorders from GSE in an effective way, but to date, TCRγδ immunohistochemistry in early and latent GSE remains still controversial[24,73]. Moreover, the initial attempts to perform an assay using formalin-fixed and paraffin-embedded tissue blocks have been in vain[24]. In refractory gluten-sensitive enteropathy (RGSE), a term used to define a pathological condition affecting the small bowel, histologically resembling GSE but not responding to a strict gluten-free diet (GFD) of at least 6 mo[74]. In RGSE, most IELs have an abnormal immuophenotype, characterized by intracytoplasmic CD3ε and CD103 and loss of expression of CD3, CD4 or CD8 as well as TCR on their cell surface in 52%-98% of cases associated with a restricted rearrangement of the TCRγ gene[74,75]. In about ¾ of patients with refractory sprue, clonal TCRγ gene rearrangement is seen and the CD3 T cell lymphocytes of the lamina propria are constituted by a mixture of both CD4 and CD8 T-lymphocytes[67]. Type I RGSE is characterized by a normal T-cell phenotype (CD3+/CD8+), while type II RGSE shows loss of CD8 expression and clonality by molecular investigations. Type II RGSE may progress to enteropathy-associated T-cell lymphoma. In addition to the absolute number of IELs, the distribution of CD8-positive, CD3-positive T-lymphocytes along the villous has been observed to vary in GSE as well as in RGSE.

**GSE-MIMICKERS – “*COMMON, LESS COMMON AND HIGHLY UNCOMMON*”**

GSE mimickers are defined as diseases that may mimic GSE leaving the patients to a wrong clinical management. The Latin poet Virgil (70-19 BC) wrote in his book of the Georgics of the 1st century BC a quite famous sentence ‘*Felix, qui potuit rerum cognoscere causas*’ (literally translated as: Privileged who was able to know the causes of things) that may be appropriate in this context. IELs alone may not be diagnostic of GSE, because there are many GSE mimickers. In determinate situations, the location of IELs may help. Top or apical IEL may be suggestive of GSE and particularly of latent GSE or GSE at early stage with preserved villous architecture. IELs are more likely to decrease along the villous tip in non-GSE, laterally located and patchy distributed IEL may be seen in inflammatory bowel disease (IBD), while low down cryptically located IEL may suggest graft versus host disease (GvHD) or allograft rejection in an appropriate clinical setting. The initial manifestation of an IBD has been indeed recorded in the duodenum, before changes occur in the terminal ileum or large bowel. Focal acute inflammation is defined by the presence of a cluster of more than one (> 1) neutrophilic granulocyte in the lamina propria or epithelium and more than one (> 1) focus in a tissue biopsy[76-78]. Some other authors suggest that neutrophilic granulocytes may be normal components of the lamina propria, provided no invasion of the crypt or surface epithelium is detected[29], but we do not agree because of the specific nature of this inflammatory cell. Focal acute duodenitis is not a sensitive feature in Crohn disease, but has high specificity (92%) and high predictive value (93%-95%)[78] . Precursors of aphthoid ulcers may be considered foci of acute inflammation detected in the surface epithelium and deep stroma of the duodenum. The duodenum is also affected by acute inflammation with or without stomach involvement, but the incidence of granulomas is quite variable depending on the age of the patients and duration of the disease. The interobserver variability of interpreting duodenal biopsies may show different kappa factor depending from the institution[60,79]. IEL distribution seems to be highly sensitive, but it may require additional training in the interpretation of the histology of the upper gastrointestinal tract. The diagnosis of GSE may remain problematic, because no single test shows 100% sensitivity and 100% specificity in every patient[12]. GSE mimickers may be indeed behind the scene and there is undoubtedly no other field in gastroenterology better refigured by the Virgilian sentence (Figures 2-6).

The three most common GSE mimickers are gastric *Helicobacter pylori* (*H. pylori*) infection, and medications, especially NSAIDs or proton-pump inhibitors (PPI) use, and inflammatory bowel disease (IBD)[80]. *H. pylori* infection is associated with chronic active gastritis, ulcer disease, chronic active duodenitis and bulbitis, while non-specific duodenitis or peptic duodenitis is a condition associated with acid injury. *H. pylori* infection is typically associated with duodenal gastric metaplasia, characterized by foci of gastric-type mucus-secreting cells interspersed between duodenal enterocytes, which may be easily recognized by the periodic acid Schiff (PAS)-positivity of the containing neutral mucin and the lack of the brush border[81,82]. An increased IEL count is observed in the duodenum of patients with *H. pylori* gastritis[9,15,83,84]. There is still some debate about the specificity of the findings and more longitudinal studies may be needed, but in any case, correlation with serology and gastric biopsies is still recommended. The use of NSAIDs has been associated in a few cases of duodenal IEL[85,86]. Brunner gland hyperplasia, originally thought as a feature of peptic duodenitis, is now considered not relevant, because it may be encountered in the normal duodenum as well[29]. Other medications associated with villous architectural changes include colchicine, mycofenolate mofetil, ipilimumab, and several chemotherapy agents or radio-/chemotherapy protocols among others. Both Crohn disease and ulcerative colitis may have IELs in the duodenum[76,87-90]. Duodenal granulomata are a very helpful finding in confirming the diagnosis of Crohn’s disease, but they are seen in less than half of the patients. In patients with classical presentation of Crohn’s disease, villous shortening accompanied by neutrophil-rich inflammation, edema in the lamina propria, and crypt abscesses may also be encountered. Crucial is the correlation with biopsy findings arising from other sites, because isolated duodenal Crohn disease is extremely rare [91]. In up to ¼ of patients with ulcerative colitis, variable villous blunting, inflammatory expansion of the lamina propria by plasma cells, and active (neutrophilic) inflammation are also seen[90,92,93]. Food allergy, infections, small intestine bacterial overgrowth, tropical sprue, and various immunological or autoimmune disorders have been described, but are less common. Uncommon events with IEL and villous blunting may include sickle cell anemia-duodenitis with a potential ischemic background due to pileup of abnormally shaped erythrocytes[94,95] and non-*H. pylori* infection such as *Yersinia enterocolitis* and *Salmonella spp*.[96,97]. Food allergy enteropathy (FAE) and cow’s milk protein-sensitive enteropathy (CMSE) may be encountered in a duodenal biopsy and both conditions may show a wide variety of mucosal lesions in any part of the upper and lower gut. Although villous atrophy is not seen in food allergy, crypt hyperplasia and an increased number of inflammatory cells, particularly eosinophilic granulocytes, are detected more often in the lamina propria and rarely also in the surface epithelium[32,33,98-103]. In CMSE, the villous architecture is usually normal, but cytotoxic IEL count is increased, particularly in the descending part of the duodenum in contrast to GSE, which conversely shows most severe changes in the proximal parts of the duodenum[104-109]. Infections that are commonly seen in the duodenum include giardiasis, cryptosporidiosis, microsporidiosis, cyclosporosis, isosporosis, Whipple’s disease, MAI, visceral leishmaniosis, cryptococcosis, and cytomegalovirus. The clinical history with the most recent travel history of both parents and children, the geographical settings and the age of the patient may aim to restrict the diagnosis that needs to be confirmed by the laboratory and microbiologic analysis. Morphologically, *Giardia lamblia* is a pear-shaped microorganism if cut lengthwise and a binucleate, ventral disc if cut frontally with four pairs of flagella, *cryptosporidia* are basophilic merozoites (2-5 μm) of varying size, *microsporidia* are supranuclear parasitophorous vacuoles indenting the nucleus, *cyclospora* are round and fusiform merozoites (up to 6 μm in length) supra-nuclear parasitephorous vacuoles, *Isosporas* are subnuclear parasitophorous vacuoles (20-30 μm) containing banana-shaped merozoites and sexual forms, *T. Whippelii* are PAS-positive bacilli, while *intracellular M. avia* are acid fast and diastase-resistant (D-)PAS-positive curved bacilli, L. donovani are 1-2 μm basophilic amastigotes in an identifiable parasitophorous vacuole, Criptococci are microorganisms with narrow-neck budding, while the characteristic aspect of Cytomegalovirus is the “owl’s eye”, which displays a dense nuclear inclusion and granular cytoplasmic inclusions. In Table 3 the differential diagnosis of these microorganisms with the histological changes observed in the duodenum are summarized. Autoimmune enteropathy (AIE) is another GSE-mimicker because it is characterized by villous atrophy unresponsive to a GFD[25,110]. The histological evidence of enteropathy, a lack of any triggering food protein, anti-enterocyte antibodies as well as persistent diarrhea after prolonged fasting and presence of organ specific serum antibodies are essential for the diagnosis of this entity. The histology of AIE is characterized by variable degrees of architectural changes, including normal to total villous atrophy and a CD8-predominant immunophenotype of IELs. IEL count may be normal or increased and is mainly characterized by CD8-positive lymphocytes. Importantly, the number of lymphocytes harboring γδ immunophenotype is normal in both surface epithelium and lamina propria helping distinguishing AIE from GSE. AIE may produce subtotal villous blunting and IEL simulating the appearance of GSE, but the absence of goblet cells and Paneth cells in AIE biopsies accompanied by a prominent crypt apoptosis are helpful clues[29]. Common variable immunodeficiency (CVID) may also manifest with gastrointestinal symptoms, being the second most common primary immunodeficiency and its diagnosis relies on recurrent infections, decreased IgG levels at least 2-standard deviations below normal with at least decreased levels of one other immunoglobulin subclass, exclusion of other causes of immunodeficiency, and a failure to mount a response to vaccination. In 2/3 of patients with CVID undergoing endoscopy, the duodenal biopsy shows IEL with or without villous architectural changes and two CVID characteristic clues are the paucity or absence of plasma cells with prominent crypt apoptosis in CVID[29,111-113]. Graft versus host disease (GvHD) and Allograft Bowel Rejection (AGBR) may be ruled out on clinical settings. GvHD may, however, come to the gastroenterologist or pathologist who are not provided of the history of bone marrow transplantation for instance. GvHD may have, although uncommonly, an increased IEL count in proximal small bowel biopsies. A decrescendo from base to apical villi and the finding of epithelial cell apoptosis in the deep crypts with or without some degree of architectural disturbance together with the clinical setting may help to address this diagnosis[114]. Collagenous Sprue (COS) is an GSE mimicker, originally described by Weinstein in 1970[115] and shares several aspects of GSE, including villous architectural abnormalities, IEL, and crypt hyperplasia, but an irregularly thickened layer of type 1 collagen just subjacent to the surface epithelium is extremely useful for distinguishing COS from GSE. A monotypic, truncated immunoglobulin α heavy chain lacking an associated light chain secreted by plasma cells infiltrating the bowel wall characterizes a condition called immunoproliferative small-intestine disease (IPSID), which is a MALT lymphoma[116-118]. The early stages of IPSID may be quite challenging, because the duodenal mucosa may appear normal or near-normal, but thickening, erythema and nodularity of the mucosal folds may be observed in the duodenum and upper jejunum at later stages[117]. IPSID is mostly reported in individuals from the Middle East, North and South Africa and the Far East and the epidemiological background may be quite helpful.

Several immune-related disorders, including Hashimoto thyroiditis, Graves’ disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus may cause IEL. These diseases need carefully to be rule out by both clinical and laboratory grounds. Other etiologic factors that have been associated with IEL are quite more uncommon and infrequently associated to IEL, but they also need clinical and laboratory correlation. These disorders involve mainly the nervous system, whose two major diseases include autism and multiple sclerosis[119,120].

The enteropathy-type intestinal T-cell lymphoma (EITL) may be considered a complication of long-standing GSE[121-123]. EITL is frequently multifocal with ulcerative lesions and a tendency to perforate either at presentation or during chemotherapy. Histologically, there is a pleomorphic medium-to-large cell population constituted by the expression of CD3 and lack of CD4 and CD8 expressions as well as a small and monomorphic cell population characterized by the expression of CD3, CD8 and CD56 and lack of CD4 expression. CD30 is always present in the tumor cells and may be seen in the adjacent villi of the lymphoma lesions and is considered an ominous marker for prognosis. Among neoplastic GSE mimickers should be listed tubular adenomas, post-transplant lymphoproliferative disorders (PTLDs) and lymphomas.

**GSE – CHALLENGES ACROSS OCEANS**

In 2012 [16], the guidelines for CD diagnosis have been issued by the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) suggesting that biopsies can be avoided in patients who have positive HLA-DQ test results. It has been suggested that HLA-DQ test may extend beyond these cases[41]. One of the main inhibitions in efficiently using molecular biology techniques is the cost and the lack of automation, but RT-PCR, digital PCR, and Next-Generation-Sequencing (NGS) may open today interesting possibilities in tailoring the diagnostic algorithm for GSE in a more efficient way. The combined use of aTTG and anti-DGP assay is now recommended in young children, while HLA-DQ typing is useful in support of histology in seronegative patients, and to exclude patients at high risk for GSE. In patients with low risk to develop GSE, the presence of IgA aTTG positive blood inclines towards endoscopy and duodenal biopsy. ESPGHAN emphasizes that patients with selective IgA deficiency should be tested for anti-DGP IgG and/or aTTG IgG and, if positive a biopsy needs to be performed. The guidelines of the American College of Gastroenterology (ACG) and World Gastroenterology Organization (WGO) are similar, but differences have been identified recently[41]. These two guidelines distinguish between patients at low and high risk of GSE and in screening the general population, with a GSE prevalence of 1%, the IgA aTTG and DGP assays are now recommended, either simultaneously, or in sequence. Thus, in the high-risk population, only one test is considered sufficient, because in these patients it is supposed that additional tests do not increase the reliability of screening results. Conversely, in low-risk patients, a positive serological test is a strong indication for duodenal biopsy that remains the gold standard in North America. Patients at risk of GSE, biopsy is always recommended irrespective of serological results and if the results of both tests are positive, the diagnosis of GSE is confirmed. Conversely, if the serology is positive and histology is negative, it has been suggested that the biopsy is repeated at least after one year. If the histology is positive and serology is negative, HLA-DQ typing is counselled and other possible causes of duodenitis should be carefully evaluated. GSE is ruled out only when both serology and histology are negative. In Table 4, the main differences between the GSE guidelines across oceans are presented[41].

**DUODENAL MUCOSA-SYNOPTIC REPORT**

An integrated assessment of the histopathology elementary lesions and clinical and serological findings make consistent and reliable the diagnosis of GSE. The elementary lesions consist of (1) *increased intraepithelial T lymphocytes* (IELs) or Intraepithelial Lymphocytosis (IEL) with a value between 20 and 29 IEL/100 enterocytes as borderline and *≥*30 IEL/100 enterocytes representing a pathological lymphocytic infiltration of the surface epithelium; (2) *decreased height of the enterocytes* with flattening of enterocytes, intracytoplasmic vacuolation as well as reduction or absence of brush-border; (3) *crypt hyperplasia* as indicated as extension of the regenerative epithelial crypts associated with changes in the presence of more than 1 mitosis per crypt; and (4) *villous blunting* identified as decrease in villous height, alteration of normal crypt/villous ratio (3:1) until total disappearance of villi with proper orientation of the biopsies[124]. A synoptic report is commonly used for cancer pathologies using checklists that allow a better management of patients with oncological disease[125,126]. Free text reports often demonstrate significantly impaired data collection when recording several parameters and the number of words used is also significantly reduced using pre-formatted structured reports compared to free text reports. In public healthcare, the introduction of a structured reporting dictation template improves remarkably data collection and reduces the subsequent administrative burden when dealing with phone calls and / or reviewing the number of cases reviewed at multidisciplinary team meetings and external quality assurance programs provide a support for it [127]. In our opinion, a biopsy report should include the number and site of the biopsy specimens, the pathology or normality of the tissue specimens, the villous-crypt ratio (VCR), the villous architecture (normal or blunted, partial/total), the IELs count at the top, side, and down, the morphology of the surface enterocytes (normal, flattened or damaged) with or without preservation or loss of the brush border, crypt hyperplasia, gastric metaplasia (*e.g.,* chronic duodenitis), presence of microorganisms (*e.g.,* *Giardia lamblia*, cryptosporidia, microsporidia, *Isospora belli*, cyclospora, *Mycobacterium avium intracellulare*, cytomegalovirus, *Cryptococcus neoformans*)[24]. A number of additional features have been suggested to be present in the histopathologic report[71,128]. These include the search for potential benign, dysplastic or neoplastic lesions (*e.g*., adenoma or carcinoma, carcinoid, lymphoma). In Figure 6 is displayed a synoptic report that may be considered useful for both clinics and research.

**CONCLUSIONS AND FUTURE PERSPECTIVES**

Partial and patchy villous blunting may be found in cow’s milk protein-sensitive enteropathy (CMSE), in postenteritis enteropathy and in GSE. Thus, multiple biopsies should be taken to minimise the risk of misdiagnosis. The bulb mucosa may be the only duodenal area affected and total or moderate villous atrophy may affect the duodenal bulb exclusively with a normal distal duodenum. Therefore, careful appreciation with regard to whether specimens are taken from the bulb or the descending part of the duodenum is essential[129]. GSE is a common cause of an increased IEL count in the duodenum accounting probably for up half of the cases, but GSE mimickers should be taken into account. New molecular biology-supported methodologies may tailor and individualize the diagnostic algorithm in the future.

**REFERENCES**

1 **Chey WD**, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA* 2015; **313**: 949-958 [PMID: 25734736 DOI: 10.1001/jama.2015.0954]

2 **Catassi C**, Elli L, Bonaz B, Bouma G, Carroccio A, Castillejo G, Cellier C, Cristofori F, de Magistris L, Dolinsek J, Dieterich W, Francavilla R, Hadjivassiliou M, Holtmeier W, Körner U, Leffler DA, Lundin KE, Mazzarella G, Mulder CJ, Pellegrini N, Rostami K, Sanders D, Skodje GI, Schuppan D, Ullrich R, Volta U, Williams M, Zevallos VF, Zopf Y, Fasano A. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria. *Nutrients* 2015; **7**: 4966-4977 [PMID: 26096570 DOI: 10.3390/nu7064966]

3 **Jensen ET**, Eluri S, Lebwohl B, Genta RM, Dellon ES. Increased Risk of Esophageal Eosinophilia and Eosinophilic Esophagitis in Patients With Active Celiac Disease on Biopsy. *Clin Gastroenterol Hepatol* 2015; **13**: 1426-1431 [PMID: 25724709 DOI: 10.1016/j.cgh.2015.02.018]

4 **Ontiveros N**, Hardy MY, Cabrera-Chavez F. Assessing of Celiac Disease and Nonceliac Gluten Sensitivity. *Gastroenterol Res Pract* 2015; **2015**: 723954 [PMID: 26064097 DOI: 10.1155/2015/723954]

5 **Ludvigsson JF**, Card TR, Kaukinen K, Bai J, Zingone F, Sanders DS, Murray JA. Screening for celiac disease in the general population and in high-risk groups. *United European Gastroenterol J* 2015; **3**: 106-120 [PMID: 25922671 DOI: 10.1177/2050640614561668]

6 **Thakkar K**, Chen L, Tessier ME, Gilger MA. Outcomes of children after esophagogastroduodenoscopy for chronic abdominal pain. *Clin Gastroenterol Hepatol* 2014; **12**: 963-969 [PMID: 24016631 DOI: 10.1016/j.cgh.2013.08.041]

7 **Barratt SM**, Leeds JS, Sanders DS. Factors influencing the type, timing and severity of symptomatic responses to dietary gluten in patients with biopsy-proven coeliac disease. *J Gastrointestin Liver Dis* 2013; **22**: 391-396 [PMID: 24369320]

8 **Klapp G**, Masip E, Bolonio M, Donat E, Polo B, Ramos D, Ribes-Koninckx C. Celiac disease: the new proposed ESPGHAN diagnostic criteria do work well in a selected population. *J Pediatr Gastroenterol Nutr* 2013; **56**: 251-256 [PMID: 23111763 DOI: 10.1097/MPG.0b013e318279887b]

9 **Shmidt E**, Smyrk TC, Faubion WA, Oxentenko AS. Duodenal intraepithelial lymphocytosis with normal villous architecture in pediatric patients: Mayo Clinic experience, 2000-2009. *J Pediatr Gastroenterol Nutr* 2013; **56**: 51-55 [PMID: 22785416 DOI: 10.1097/MPG.0b013e318267c353]

10 **Keswani RN**, Early DS, Edmundowicz SA, Meyers BF, Sharma A, Govindan R, Chen J, Kohlmeier C, Azar RR. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. *Gastrointest Endosc* 2009; **69**: 1210-1217 [PMID: 19012886 DOI: 10.1016/j.gie.2008.08.016]

11 **Lee HY**, Kim SH, Lee JM, Kim SW, Jang JY, Han JK, Choi BI. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. *Radiology* 2006; **239**: 113-121 [PMID: 16467211 DOI: 10.1148/radiol.2383050419]

12 NIH Consensus Development Conference on Celiac Disease. *NIH Consens State Sci Statements* 2004; **21**: 1-23 [PMID: 17308551]

13 **Goldstein NS**. Proximal small-bowel mucosal villous intraepithelial lymphocytes. *Histopathology* 2004; **44**: 199-205 [PMID: 14987222]

14 **Suntharalingam M**, Moughan J, Coia LR, Krasna MJ, Kachnic L, Haller DG, Willett CG, John MJ, Minsky BD, Owen JB. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. *Int J Radiat Oncol Biol Phys* 2003; **56**: 981-987 [PMID: 12829133]

15 **Guz-Mark A**, Zevit N, Morgenstern S, Shamir R. Duodenal intraepithelial lymphocytosis is common in children without coeliac disease, and is not meaningfully influenced by Helicobacter pylori infection. *Aliment Pharmacol Ther* 2014; **39**: 1314-1320 [PMID: 24702235 DOI: 10.1111/apt.12739]

16 **Husby S**, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Mäki M, Ribes-Koninckx C, Ventura A, Zimmer KP. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr* 2012; **54**: 136-160 [PMID: 22197856 DOI: 10.1097/MPG.0b013e31821a23d0]

17 **Freeman HJ**. Celiac disease: a disorder emerging from antiquity, its evolving classification and risk, and potential new treatment paradigms. *Gut Liver* 2015; **9**: 28-37 [PMID: 25547088 DOI: 10.5009/gnl14288]

18 **Cenit MC**, Olivares M, Codoñer-Franch P, Sanz Y. Intestinal Microbiota and Celiac Disease: Cause, Consequence or Co-Evolution? *Nutrients* 2015; **7**: 6900-6923 [PMID: 26287240 DOI: 10.3390/nu7085314]

19 **Dieli-Crimi R**, Cénit MC, Núñez C. The genetics of celiac disease: A comprehensive review of clinical implications. *J Autoimmun* 2015; **64**: 26-41 [PMID: 26194613 DOI: 10.1016/j.jaut.2015.07.003]

20 **Withoff S**, Li Y, Jonkers I, Wijmenga C. Understanding Celiac Disease by Genomics. *Trends Genet* 2016; **32**: 295-308 [PMID: 26972670 DOI: 10.1016/j.tig.2016.02.003]

21 **Corfield A**, Meyer P, Kassam S, Mikuz G, Sergi C. SNPs: At the origins of the databases of an innovative biotechnology tool. *Front Biosci (Schol Ed)* 2010; **2**: 1-4 [PMID: 20036923]

22 **Meyer P**, Sergi C, Garbe C. Polymorphisms of the BRAF gene predispose males to malignant melanoma. *J Carcinog* 2003; **2**: 7 [PMID: 14617374 DOI: 10.1186/1477-3163-2-7]

23 **Lumb R**, Schwarz Q. Sympathoadrenal neural crest cells: the known, unknown and forgotten? *Dev Growth Differ* 2015; **57**: 146-157 [PMID: 25581786 DOI: 10.1111/dgd.12189]

24 **Serra S**, Jani PA. An approach to duodenal biopsies. *J Clin Pathol* 2006; **59**: 1133-1150 [PMID: 16679353 DOI: 10.1136/jcp.2005.031260]

25 **Murch S**. Recent Advances in Celiac Disease. *Indian J Pediatr* 2016; **83**: 1428-1435 [PMID: 27278238 DOI: 10.1007/s12098-016-2161-8]

26 **Hvas CL**, Jensen MD, Reimer MC, Riis LB, Rumessen JJ, Skovbjerg H, Teisner A, Wildt S. Celiac disease: diagnosis and treatment. *Dan Med J* 2015; **62**: C5051 [PMID: 25872537]

27 **van Wanrooij RL**, Müller DM, Neefjes-Borst EA, Meijer J, Koudstaal LG, Heideman DA, Bontkes HJ, von Blomberg BM, Bouma G, Mulder CJ. Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractory coeliac disease. *J Clin Immunol* 2014; **34**: 828-835 [PMID: 25062848 DOI: 10.1007/s10875-014-0075-7]

28 **Mehta P**, Furuta GT. Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. *Immunol Allergy Clin North Am* 2015; **35**: 413-437 [PMID: 26209893 DOI: 10.1016/j.iac.2015.04.003]

29 **Pai RK**. A practical approach to small bowel biopsy interpretation: celiac disease and its mimics. *Semin Diagn Pathol* 2014; **31**: 124-136 [PMID: 24815938 DOI: 10.1053/j.semdp.2014.02.006]

30 **Biagi F**, Luinetti O, Campanella J, Klersy C, Zambelli C, Villanacci V, Lanzini A, Corazza GR. Intraepithelial lymphocytes in the villous tip: do they indicate potential coeliac disease? *J Clin Pathol* 2004; **57**: 835-839 [PMID: 15280404 DOI: 10.1136/jcp.2003.013607]

31 **Dickey W**, Hughes DF. Histology of the terminal ileum in coeliac disease. *Scand J Gastroenterol* 2004; **39**: 665-667 [PMID: 15370688 DOI: 10.1080/00365520410004901]

32 **Carroccio A**, D'Alcamo A, Cavataio F, Soresi M, Seidita A, Sciumè C, Geraci G, Iacono G, Mansueto P. High Proportions of People With Nonceliac Wheat Sensitivity Have Autoimmune Disease or Antinuclear Antibodies. *Gastroenterology* 2015; **149**: 596-603.e1 [PMID: 26026392 DOI: 10.1053/j.gastro.2015.05.040]

33 **Mansueto P**, D'Alcamo A, Seidita A, Carroccio A. Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity. *World J Gastroenterol* 2015; **21**: 7089-7109 [PMID: 26109796 DOI: 10.3748/wjg.v21.i23.7089]

34 **Biagi F**, Marchese A, Ferretti F, Ciccocioppo R, Schiepatti A, Volta U, Caio G, Ciacci C, Zingone F, D'Odorico A, Carroccio A, Ambrosiano G, Mansueto P, Gasbarrini A, Piscaglia AC, Andrealli A, Astegiano M, Segato S, Neri M, Meggio A, de Pretis G, De Vitis I, Gobbi P, Corazza GR. A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses. *BMC Gastroenterol* 2014; **14**: 139 [PMID: 25103857 DOI: 10.1186/1471-230X-14-139]

35 **Brusca I**, Carroccio A, Tonutti E, Villalta D, Tozzoli R, Barrale M, Sarullo FM, Mansueto P, Chiusa SM, Iacono G, Bizzaro N. The old and new tests for celiac disease: which is the best test combination to diagnose celiac disease in pediatric patients? *Clin Chem Lab Med* 2011; **50**: 111-117 [PMID: 21942854 DOI: 10.1515/CCLM.2011.714]

36 **van Gils T**, Nijeboer P, van Wanrooij RL, Bouma G, Mulder CJ. Mechanisms and management of refractory coeliac disease. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 572-579 [PMID: 26347156 DOI: 10.1038/nrgastro.2015.155]

37 **Nijeboer P**, van Wanrooij RL, Tack GJ, Mulder CJ, Bouma G. Update on the diagnosis and management of refractory coeliac disease. *Gastroenterol Res Pract* 2013; **2013**: 518483 [PMID: 23762036 DOI: 10.1155/2013/518483]

38 **Mulder CJ**, van Wanrooij RL, Bakker SF, Wierdsma N, Bouma G. Gluten-free diet in gluten-related disorders. *Dig Dis* 2013; **31**: 57-62 [PMID: 23797124 DOI: 10.1159/000347180]

39 **Tack GJ**, van Wanrooij RL, Langerak AW, Tjon JM, von Blomberg BM, Heideman DA, van Bergen J, Koning F, Bouma G, Mulder CJ, Schreurs MW. Origin and immunophenotype of aberrant IEL in RCDII patients. *Mol Immunol* 2012; **50**: 262-270 [PMID: 22364936 DOI: 10.1016/j.molimm.2012.01.014]

40 **van Wanrooij RL**, Schreurs MW, Bouma G, von Blomberg BM, Tack GJ, Verbeek WH, Mulder CJ. Accurate classification of RCD requires flow cytometry. *Gut* 2010; **59**: 1732 [PMID: 20805314 DOI: 10.1136/gut.2010.223438]

41 **Brusca I**. Overview of biomarkers for diagnosis and monitoring of celiac disease. *Adv Clin Chem* 2015; **68**: 1-55 [PMID: 25858867 DOI: 10.1016/bs.acc.2014.12.006]

42 **Tursi A**, Brandimarte G, Giorgetti GM. Prevalence of antitissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease. *J Clin Gastroenterol* 2003; **36**: 219-221 [PMID: 12590232]

43 **Zintzaras E**, Germenis AE. Performance of antibodies against tissue transglutaminase for the diagnosis of celiac disease: meta-analysis. *Clin Vaccine Immunol* 2006; **13**: 187-192 [PMID: 16467324 DOI: 10.1128/CVI.13.2.187-192.2006]

44 **Korponay-Szabó IR**, Troncone R, Discepolo V. Adaptive diagnosis of coeliac disease. *Best Pract Res Clin Gastroenterol* 2015; **29**: 381-398 [PMID: 26060104 DOI: 10.1016/j.bpg.2015.05.003]

45 **Kelly CP**, Bai JC, Liu E, Leffler DA. Advances in diagnosis and management of celiac disease. *Gastroenterology* 2015; **148**: 1175-1186 [PMID: 25662623 DOI: 10.1053/j.gastro.2015.01.044]

46 **Giersiepen K**, Lelgemann M, Stuhldreher N, Ronfani L, Husby S, Koletzko S, Korponay-Szabó IR. Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. *J Pediatr Gastroenterol Nutr* 2012; **54**: 229-241 [PMID: 22266486 DOI: 10.1097/MPG.0b013e318216f2e5]

47 **Fasano A**, Catassi C. Clinical practice. Celiac disease. *N Engl J Med* 2012; **367**: 2419-2426 [PMID: 23252527 DOI: 10.1056/NEJMcp1113994]

48 **Song HJ**, Shim KN. Current status and future perspectives of capsule endoscopy. *Intest Res* 2016; **14**: 21-29 [PMID: 26884731 DOI: 10.5217/ir.2016.14.1.21]

49 **Branchi F**, Locatelli M, Tomba C, Conte D, Ferretti F, Elli L. Enteroscopy and radiology for the management of celiac disease complications: Time for a pragmatic roadmap. *Dig Liver Dis* 2016; **48**: 578-586 [PMID: 27012449 DOI: 10.1016/j.dld.2016.02.015]

50 **Sheiko MA**, Feinstein JA, Capocelli KE, Kramer RE. The concordance of endoscopic and histologic findings of 1000 pediatric EGDs. *Gastrointest Endosc* 2015; **81**: 1385-1391 [PMID: 25440693 DOI: 10.1016/j.gie.2014.09.010]

51 **Kurppa K**, Taavela J, Saavalainen P, Kaukinen K, Lindfors K. Novel diagnostic techniques for celiac disease. *Expert Rev Gastroenterol Hepatol* 2016; **10**: 795-805 [PMID: 26838683 DOI: 10.1586/17474124.2016.1148599]

52 **Mearin ML**, Ivarsson A, Dickey W. Coeliac disease: is it time for mass screening? *Best Pract Res Clin Gastroenterol* 2005; **19**: 441-452 [PMID: 15925848 DOI: 10.1016/j.bpg.2005.02.004]

53 **Dickey W**, Hughes D. Erosions in the second part of the duodenum in patients with villous atrophy. *Gastrointest Endosc* 2004; **59**: 116-118 [PMID: 14722564]

54 **Moran CJ**, Kolman OK, Russell GJ, Brown IS, Mino-Kenudson M. Neutrophilic infiltration in gluten-sensitive enteropathy is neither uncommon nor insignificant: assessment of duodenal biopsies from 267 pediatric and adult patients. *Am J Surg Pathol* 2012; **36**: 1339-1345 [PMID: 22531172 DOI: 10.1097/PAS.0b013e318254f413]

55 **Pellicano R**, De Angelis C, Ribaldone DG, Fagoonee S, Astegiano M. 2013 update on celiac disease and eosinophilic esophagitis. *Nutrients* 2013; **5**: 3329-3336 [PMID: 23974065 DOI: 10.3390/nu5093329]

56 **Menard-Katcher C**, Furuta GT, Masterson JC. Mucosal inflammation, esophageal eosinophilia, and celiac disease: a little "pinch" will have to do you. *J Pediatr Gastroenterol Nutr* 2015; **60**: 427-428 [PMID: 25611031 DOI: 10.1097/MPG.0000000000000736]

57 **Furuta GT**. Eosinophilic esophagitis: update on clinicopathological manifestations and pathophysiology. *Curr Opin Gastroenterol* 2011; **27**: 383-388 [PMID: 21577101 DOI: 10.1097/MOG.0b013e328347bb10]

58 **Atkins D**, Furuta GT. Mucosal immunology, eosinophilic esophagitis, and other intestinal inflammatory diseases. *J Allergy Clin Immunol* 2010; **125**: S255-S261 [PMID: 20176262 DOI: 10.1016/j.jaci.2009.11.037]

59 **Goldstein NS**, Underhill J. Morphologic features suggestive of gluten sensitivity in architecturally normal duodenal biopsy specimens. *Am J Clin Pathol* 2001; **116**: 63-71 [PMID: 11447753 DOI: 10.1309/5PRJ-CM0U-6KLD-6KCM]

60 **Järvinen TT**, Collin P, Rasmussen M, Kyrönpalo S, Mäki M, Partanen J, Reunala T, Kaukinen K. Villous tip intraepithelial lymphocytes as markers of early-stage coeliac disease. *Scand J Gastroenterol* 2004; **39**: 428-433 [PMID: 15180179]

61 **Oberhuber G**, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. *Eur J Gastroenterol Hepatol* 1999; **11**: 1185-1194 [PMID: 10524652]

62 **Marsh MN**. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). *Gastroenterology* 1992; **102**: 330-354 [PMID: 1727768]

63 **Marsh MN**, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. *Baillieres Clin Gastroenterol* 1995; **9**: 273-293 [PMID: 7549028]

64 **Corazza GR**, Villanacci V. Coeliac disease. *J Clin Pathol* 2005; **58**: 573-574 [PMID: 15917404 DOI: 10.1136/jcp.2004.023978]

65 **Vivas S**, Vaquero L, Rodríguez-Martín L, Caminero A. Age-related differences in celiac disease: Specific characteristics of adult presentation. *World J Gastrointest Pharmacol Ther* 2015; **6**: 207-212 [PMID: 26558154 DOI: 10.4292/wjgpt.v6.i4.207]

66 **Ho-Yen C**, Chang F, van der Walt J, Mitchell T, Ciclitira P. Recent advances in refractory coeliac disease: a review. *Histopathology* 2009; **54**: 783-795 [PMID: 18700844 DOI: 10.1111/j.1365-2559.2008.03112.x]

67 **Bagdi E**, Diss TC, Munson P, Isaacson PG. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. *Blood* 1999; **94**: 260-264 [PMID: 10381521]

68 **Ishibashi H**, Nimura S, Ishitsuka K, Mihashi Y, Mizoguchi M, Nakamura S, Okamura S, Momosaki S, Aoyagi K, Sakisaka S, Takeshita M. High Expression of Intestinal Homing Receptor CD103 in Adult T-Cell Leukemia/Lymphoma, Similar to 2 Other CD8+ T-Cell Lymphomas. *Am J Surg Pathol* 2016; **40**: 462-470 [PMID: 26813744 DOI: 10.1097/PAS.0000000000000597]

69 **Morgan EA**, Pihan GA, Said JW, Yu H, Pinkus JL, Dorfman DM, Rodig SJ, Pinkus GS. Profile of CD103 expression in T-cell neoplasms: immunoreactivity is not restricted to enteropathy-associated T-cell lymphoma. *Am J Surg Pathol* 2014; **38**: 1557-1570 [PMID: 25025448 DOI: 10.1097/PAS.0000000000000296]

70 **Krauss N**, Schuppan D. Monitoring nonresponsive patients who have celiac disease. *Gastrointest Endosc Clin N Am* 2006; **16**: 317-327 [PMID: 16644460 DOI: 10.1016/j.giec.2006.03.005]

71 **Villanacci V**, Ceppa P, Tavani E, Vindigni C, Volta U. Coeliac disease: the histology report. *Dig Liver Dis* 2011; **43** Suppl 4: S385-S395 [PMID: 21459344 DOI: 10.1016/S1590-8658(11)60594-X]

72 **Hudacko R**, Kathy Zhou X, Yantiss RK. Immunohistochemical stains for CD3 and CD8 do not improve detection of gluten-sensitive enteropathy in duodenal biopsies. *Mod Pathol* 2013; **26**: 1241-1245 [PMID: 23558576 DOI: 10.1038/modpathol.2013.57]

73 **Freeman HJ**, Weinstein WM, Shnitka TK, Piercey JR, Wensel RH. Primary abdominal lymphoma. Presenting manifestation of celiac sprue or complicating dermatitis herpetiformis. *Am J Med* 1977; **63**: 585-594 [PMID: 333913]

74 **Cellier C**, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, Macintyre E, Cerf-Bensussan N, Brousse N. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. *Lancet* 2000; **356**: 203-208 [PMID: 10963198]

75 **Cellier C**, Patey N, Mauvieux L, Jabri B, Delabesse E, Cervoni JP, Burtin ML, Guy-Grand D, Bouhnik Y, Modigliani R, Barbier JP, Macintyre E, Brousse N, Cerf-Bensussan N. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. *Gastroenterology* 1998; **114**: 471-481 [PMID: 9496937]

76 **Bryant RV**, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. *J Crohns Colitis* 2014; **8**: 1582-1597 [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011]

77 **Tanaka M**, Riddell RH, Saito H, Soma Y, Hidaka H, Kudo H. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. *Scand J Gastroenterol* 1999; **34**: 55-67 [PMID: 10048734]

78 **Wright CL**, Riddell RH. Histology of the stomach and duodenum in Crohn's disease. *Am J Surg Pathol* 1998; **22**: 383-390 [PMID: 9537465]

79 **Järvinen TT**, Kaukinen K, Laurila K, Kyrönpalo S, Rasmussen M, Mäki M, Korhonen H, Reunala T, Collin P. Intraepithelial lymphocytes in celiac disease. *Am J Gastroenterol* 2003; **98**: 1332-1337 [PMID: 12818278 DOI: 10.1111/j.1572-0241.2003.07456.x]

80 **Brown I**, Mino-Kenudson M, Deshpande V, Lauwers GY. Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa: an increasing diagnostic problem with a wide differential diagnosis. *Arch Pathol Lab Med* 2006; **130**: 1020-1025 [PMID: 16831028 DOI: 10.1043/1543-2165(2006)130[1020: ILIAPP]2.0.CO; 2]

81 **Voutilainen M**, Juhola M, Färkkilä M, Sipponen P. Gastric metaplasia and chronic inflammation at the duodenal bulb mucosa. *Dig Liver Dis* 2003; **35**: 94-98 [PMID: 12747627]

82 **Memeo L**, Jhang J, Hibshoosh H, Green PH, Rotterdam H, Bhagat G. Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. *Mod Pathol* 2005; **18**: 1134-1144 [PMID: 15803187 DOI: 10.1038/modpathol.3800404]

83 **Chang F**, Mahadeva U, Deere H. Pathological and clinical significance of increased intraepithelial lymphocytes (IELs) in small bowel mucosa. *APMIS* 2005; **113**: 385-399 [PMID: 15996156 DOI: 10.1111/j.1600-0463.2005.apm\_204.x]

84 **Ernst PB**, Takaishi H, Crowe SE. Helicobacter pylori infection as a model for gastrointestinal immunity and chronic inflammatory diseases. *Dig Dis* 2001; **19**: 104-111 [PMID: 11549818 DOI: 50663]

85 **Levine A**, Domanov S, Sukhotnik I, Zangen T, Shaoul R. Celiac-associated peptic disease at upper endoscopy: how common is it? *Scand J Gastroenterol* 2009; **44**: 1424-1428 [PMID: 19883278 DOI: 10.3109/00365520903307987]

86 **Camilleri M**. Gastroenterology and hepatology clinical research update: 2005-2006. *Clin Gastroenterol Hepatol* 2006; **4**: 1428-1433 [PMID: 16949347 DOI: 10.1016/j.cgh.2006.06.027]

87 **Schedel J**, Rockmann F, Bongartz T, Woenckhaus M, Schölmerich J, Kullmann F. Association of Crohn's disease and latent celiac disease: a case report and review of the literature. *Int J Colorectal Dis* 2005; **20**: 376-380 [PMID: 15578194 DOI: 10.1007/s00384-004-0661-x]

88 **Thies F**, Masson LF, Boffetta P, Kris-Etherton P. Oats and bowel disease: a systematic literature review. *Br J Nutr* 2014; **112** Suppl 2: S31-S43 [PMID: 25267242 DOI: 10.1017/S0007114514002293]

89 **Hardee S**, Alper A, Pashankar DS, Morotti RA. Histopathology of duodenal mucosal lesions in pediatric patients with inflammatory bowel disease: statistical analysis to identify distinctive features. *Pediatr Dev Pathol* 2014; **17**: 450-454 [PMID: 25207874 DOI: 10.2350/14-07-1529-OA.1]

90 **Tobin JM**, Sinha B, Ramani P, Saleh AR, Murphy MS. Upper gastrointestinal mucosal disease in pediatric Crohn disease and ulcerative colitis: a blinded, controlled study. *J Pediatr Gastroenterol Nutr* 2001; **32**: 443-448 [PMID: 11396811]

91 **Kimmins MH**, Billingham RP. Duodenal Crohn's disease. *Tech Coloproctol* 2001; **5**: 9-12 [PMID: 11793253 DOI: 10.1007/s101510100001]

92 **Lin J**, McKenna BJ, Appelman HD. Morphologic findings in upper gastrointestinal biopsies of patients with ulcerative colitis: a controlled study. *Am J Surg Pathol* 2010; **34**: 1672-1677 [PMID: 20962621 DOI: 10.1097/PAS.0b013e3181f3de93]

93 **Rubenstein J**, Sherif A, Appelman H, Chey WD. Ulcerative colitis associated enteritis: is ulcerative colitis always confined to the colon? *J Clin Gastroenterol* 2004; **38**: 46-51 [PMID: 14679327]

94 **Gardner CS**, Jaffe TA. CT of Gastrointestinal Vasoocclusive Crisis Complicating Sickle Cell Disease. *AJR Am J Roentgenol* 2015; **204**: 994-999 [PMID: 25905933 DOI: 10.2214/AJR.14.13286]

95 **Dhiman R**, Yusif R, Nabar U, Albaqali A. Images of interest. Gastrointestinal: ischemic enteritis and sickle cell disease. *J Gastroenterol Hepatol* 2004; **19**: 1318 [PMID: 15482541 DOI: 10.1111/j.1440-1746.2004.03630.x]

96 **Abdel-Haq NM**, Asmar BI, Abuhammour WM, Brown WJ. Yersinia enterocolitica infection in children. *Pediatr Infect Dis J* 2000; **19**: 954-958 [PMID: 11055595]

97 **van Cappelle HG**, Veenendaal D, de Vogel PL. Salmonella panama osteomyelitis in an otherwise healthy patient. A case report. *Clin Orthop Relat Res* 1995;**(321):** 235-238 [PMID: 7497674]

98 **Khalid AN**, McMains KC. Gluten sensitivity: fact or fashion statement? *Curr Opin Otolaryngol Head Neck Surg* 2016; **24**: 238-240 [PMID: 27070331 DOI: 10.1097/MOO.0000000000000263]

99 **Heine RG**, Allen KJ. Eosinophilic oesophagitis. *Chem Immunol Allergy* 2015; **101**: 199-208 [PMID: 26022880 DOI: 10.1159/000371703]

100 **Allen PJ**. Gluten-Related Disorders: Celiac Disease, Gluten Allergy, Non-Celiac Gluten Sensitivity. *Pediatr Nurs* 2015; **41**: 146-150 [PMID: 26201175]

101 **Aziz I**, Hadjivassiliou M, Sanders DS. The spectrum of noncoeliac gluten sensitivity. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 516-526 [PMID: 26122473 DOI: 10.1038/nrgastro.2015.107]

102 **Kokkonen J**, Holm K, Karttunen TJ, Mäki M. Children with untreated food allergy express a relative increment in the density of duodenal gammadelta+ T cells. *Scand J Gastroenterol* 2000; **35**: 1137-1142 [PMID: 11145283]

103 **Tikkanen S**, Kokkonen J, Juntti H, Niinimäki A. Status of children with cow's milk allergy in infancy by 10 years of age. *Acta Paediatr* 2000; **89**: 1174-1180 [PMID: 11083371]

104 **Carroccio A**, Brusca I, Mansueto P, D'alcamo A, Barrale M, Soresi M, Seidita A, La Chiusa SM, Iacono G, Sprini D. A comparison between two different in vitro basophil activation tests for gluten- and cow's milk protein sensitivity in irritable bowel syndrome (IBS)-like patients. *Clin Chem Lab Med* 2013; **51**: 1257-1263 [PMID: 23183757 DOI: 10.1515/cclm-2012-0609]

105 **Agostoni C**, Decsi T, Fewtrell M, Goulet O, Kolacek S, Koletzko B, Michaelsen KF, Moreno L, Puntis J, Rigo J, Shamir R, Szajewska H, Turck D, van Goudoever J. Complementary feeding: a commentary by the ESPGHAN Committee on Nutrition. *J Pediatr Gastroenterol Nutr* 2008; **46**: 99-110 [PMID: 18162844 DOI: 10.1097/01.mpg.0000304464.60788.bd]

106 **Kagalwalla AF**, Shah A, Ritz S, Melin-Aldana H, Li BU. Cow's milk protein-induced eosinophilic esophagitis in a child with gluten-sensitive enteropathy. *J Pediatr Gastroenterol Nutr* 2007; **44**: 386-388 [PMID: 17325563 DOI: 10.1097/01.mpg.0000243430.32087.5c]

107 **Carroccio A**, Cavataio F, Iacono G, Agate V, Ippolito S, Kazmierska I, Campagna P, Soresi M, Montalto G. IgA antiendomysial antibodies on the umbilical cord in diagnosing celiac disease. Sensitivity, specificity, and comparative evaluation with the traditional kit. *Scand J Gastroenterol* 1996; **31**: 759-763 [PMID: 8858743]

108 **Augustin MT**, Kokkonen J, Karttunen TJ. Duodenal cytotoxic lymphocytes in cow's milk protein sensitive enteropathy and coeliac disease. *Scand J Gastroenterol* 2005; **40**: 1398-1406 [PMID: 16293554 DOI: 10.1080/00365520510023765]

109 **Augustin MT**, Kokkonen J, Karttunen R, Karttunen TJ. Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease. *J Allergy Clin Immunol* 2005; **115**: 157-162 [PMID: 15637563 DOI: 10.1016/j.jaci.2004.10.009]

110 **Lauret E**, Rodrigo L. Celiac disease and autoimmune-associated conditions. *Biomed Res Int* 2013; **2013**: 127589 [PMID: 23984314 DOI: 10.1155/2013/127589]

111 **Giorgio F**, Principi M, Losurdo G, Piscitelli D, Iannone A, Barone M, Amoruso A, Ierardi E, Di Leo A. Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg? *Nutrients* 2015; **7**: 7486-7504 [PMID: 26371035 DOI: 10.3390/nu7095350]

112 **Biagi F**, Bianchi PI, Zilli A, Marchese A, Luinetti O, Lougaris V, Plebani A, Villanacci V, Corazza GR. The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study. *Am J Clin Pathol* 2012; **138**: 185-189 [PMID: 22904128 DOI: 10.1309/AJCPEIILH2C0WFYE]

113 **Daniels JA**, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. *Am J Surg Pathol* 2007; **31**: 1800-1812 [PMID: 18043034 DOI: 10.1097/PAS.0b013e3180cab60c]

114 **Goldman H**, Antonioli DA. Mucosal biopsy of the esophagus, stomach, and proximal duodenum. *Hum Pathol* 1982; **13**: 423-448 [PMID: 7076225]

115 **Weinstein WM**, Saunders DR, Tytgat GN, Rubin CE. Collagenous sprue--an unrecognized type of malabsorption. *N Engl J Med* 1970; **283**: 1297-1301 [PMID: 5478450 DOI: 10.1056/NEJM197012102832401]

116 **Shirsat HS**, Vaiphei K. Primary gastrointestinal lymphomas - A study of 81 Cases from a Tertiary Healthcare Centre. *Indian J Cancer* 2014; **51**: 290-292 [PMID: 25494124 DOI: 10.4103/0019-509X.146777]

117 **Al-Saleem T**, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. *Blood* 2005; **105**: 2274-2280 [PMID: 15542584 DOI: 10.1182/blood-2004-07-2755]

118 **Isaacson PG**. Gastrointestinal lymphomas of T- and B-cell types. *Mod Pathol* 1999; **12**: 151-158 [PMID: 10071340]

119 **Cruchet S**, Lucero Y, Cornejo V. Truths, Myths and Needs of Special Diets: Attention-Deficit/Hyperactivity Disorder, Autism, Non-Celiac Gluten Sensitivity, and Vegetarianism. *Ann Nutr Metab* 2016; **68** Suppl 1: 43-50 [PMID: 27356007 DOI: 10.1159/000445393]

120 **Casella G,** Bordo BM, Schalling R, Villanacci V, Salemme M, Di Bella C, Baldini V, Bassotti G.. Neurological disorders and celiac disease. *Minerva Gastroenterol Dietol* 2016 [PMID: 26619901]

121 **Tanaka T**, Yamamoto H, Elsayed AA, Satou A, Asano N, Kohno K, Kinoshita T, Niwa Y, Goto H, Nakamura S, Kato S. Clinicopathologic Spectrum of Gastrointestinal T-cell Lymphoma: Reappraisal Based on T-cell Receptor Immunophenotypes. *Am J Surg Pathol* 2016; **40**: 777-785 [PMID: 26975035 DOI: 10.1097/PAS.0000000000000630]

122 **Hong YS**, Woo YS, Park G, Lee K, Kang SH, Lee HW, Kim ER, Hong SN, Chang DK, Kim YH, Rhee PL, Kim JJ. Endoscopic Findings of Enteropathy-Associated T-Cell Lymphoma Type II: A Case Series. *Gut Liver* 2016; **10**: 147-151 [PMID: 26260757 DOI: 10.5009/gnl14457]

123 **Malamut G**, Cellier C. Complications of coeliac disease. *Best Pract Res Clin Gastroenterol* 2015; **29**: 451-458 [PMID: 26060109 DOI: 10.1016/j.bpg.2015.05.005]

124 **Carroccio A**, Di Prima L, Noto D, Fayer F, Ambrosiano G, Villanacci V, Lammers K, Lafiandra D, De Ambrogio E, Di Fede G, Iacono G, Pogna N. Searching for wheat plants with low toxicity in celiac disease: Between direct toxicity and immunologic activation. *Dig Liver Dis* 2011; **43**: 34-39 [PMID: 20554485 DOI: 10.1016/j.dld.2010.05.005]

125 **King S**, Dimech M, Johnstone S. Structured pathology reporting improves the macroscopic assessment of rectal tumour resection specimens. *Pathology* 2016; **48**: 349-352 [PMID: 27114373 DOI: 10.1016/j.pathol.2016.03.003]

126 **Sluijter CE**, van Lonkhuijzen LR, van Slooten HJ, Nagtegaal ID, Overbeek LI. The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review. *Virchows Arch* 2016; **468**: 639-649 [PMID: 27097810 DOI: 10.1007/s00428-016-1935-8]

127 **Sergi C**, Mikuz G. External quality assurance as a revalidation method for pathologists in pediatric histopathology: Comparison of four international programs. *BMC Clin Pathol* 2008; **8**: 11 [PMID: 19014480 DOI: 10.1186/1472-6890-8-11]

128 **Villanacci V**. The histological classification of biopsy in celiac disease: time for a change? *Dig Liver Dis* 2015; **47**: 2-3 [PMID: 25453867 DOI: 10.1016/j.dld.2014.09.022]

129 **Bednarska O**, Ignatova S, Dahle C, Ström M. Intraepithelial lymphocyte distribution differs between the bulb and the second part of duodenum. *BMC Gastroenterol* 2013; **13**: 111 [PMID: 23841671 DOI: 10.1186/1471-230X-13-111]

**P-Reviewer:** Demir Y, ParsiMAA **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Canada

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Updated marsh-oberhuber classification of gse (5 states of sb-mucosal injury 0–4)**

● **Type 0**: Pre-infiltrative: normal V: C Ratio and crypts with less than 20 IELs per 100 enterocytes (1:5)

● **Type 1**: Infiltrative type: normal V: C Ratio and crypts, but ↑ IELs (>20 IELs / 100 enterocytes)

● **Type 2**: Infiltrative-hyperplastic type: normal V: C Ratio, but crypt hyperplasia with ↑ IELs

● **Type 3**: Destructive (flat mucosa) type of GSE lesion according to the degree of villous atrophy

● Type 3a: *Mild* villous atrophy with V: C <3 1, and ↑IELs

● Type 3b: *Marked* villous atrophy with V: C <1 1, and ↑ IELs

● Type 3c: *Total* villous atrophy with completely flat mucosa and ↑ IELs

● **Type 4**: Atrophic type *(hypoplastic)*; *flat* mucosa with only a few crypts and near-normal IEL count

V: C: Villous to crypt ratio (normal, V:C > 3:1); GSE: Gluten-sensitive enteropathy; IEL: Intraepithelial lymphocytes.

**Table 2 Corazza-Villanacci classification**

● Grade A: *Nonatrophic*, with normal V: C Ratio and ↑ IELs (> 25 IELs/100 enterocytes)

● Grade B1: *’Atrophic’*, V: C < 3: 1, but villi still detectable and ↑ IELs (> 25 IELs/100 enterocytes)

● Grade B2: *Atrophic* and flat, villi not detectable and ↑ IELs (> 25 IELs per 100 enterocytes)

V:C: Villous to crypt ratio (normal, V: C > 3: 1); GSE: Gluten-sensitive enteropathy; IEL: Intraepithelial lymphocytes.

**Table 3 Most Common duodenal infections potentially mimicking gluten-sensitive enteropathy**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Agent** | **Villi** | **CH** | **LPI** | **IELs** | **PMNs** | **Sup.-D.** | **Target** | **Site** | **Stain** |
| Giardiasis | G. lamblia | 0-3A | Nil | 0/+/++ | < 20/↑ | Rarely | Nil | None | IL | GS |
| Cryptosporidia | C. parvum | 1-3A | + | +/++ | < 20 | Focal | Focally | Enterocytes | IE | WS |
| Microsporidia | E. bieneusi  E. intestinalis | 1-3A | + | +/++ | < 20 | Nil | Focally | Enterocytes/ Macrophages | IEv/ IEc | WS |
| Cyclospora | C. coyetanensis | 1-3A | + | +/++ | < 20/↑ | Nil | Focally | Enterocytes | IEv | NA |
| Isospora | I. belli | 1-3A | + | +/++ | < 20 | Nil | Focally | Enterocytes | IEv | NA |
| Whipple D. | T. whippeli | 1-3A | Nil | ++1 | ↑ | Nil | Nil | Macrophages | LP | PAS ZN |
| MAI | M. avium intracellulare | 1-3A | Nil | ++1 | < 20 | Nil | Nil | Macrophages | LP | PAS ZN AR |
| Leishmaniasis | L. donovani | 1-3A | Nil | +/++ | < 20 | Nil | Nil | Macrophages | LP | NA |
| Cryptococcosis | C. neoformans | 1-3A | Nil | 0/+ | < 20 | Nil | Nil | None | LP | DPAS MS |
| CMV | Cytomegalovirus | ulcers | 2 | +/++ | < 20/↑ | +/- | Focally | Epithelium/ Endothelium | LP | IHC |


1Pale macrophages; 2Crypt damage; IIIA partial atrophy, IIIB subtotal atrophy, IIIC total atrophy. 0-3A: 0, no inflammation, 1, IELs, 2 mild hyperplasia / mild inflammation. IL: Intraluminal; IE: Intraepithelial (surface and crypt epithelium); IEv: Intraepithelial at the villous tips; IEc: Intraepithelial at the crypts; LP: Lamina propria; CH: Crypt hyperplasia; AR: Auramine-rhodamine stain; DPAS: Diastase-periodic acid Schiff stain; GS: Giemsa stain; IHC: Immunohistochemistry with antibodies against the CMV antigens; MS: Methenamine-silver stain; WS: Warthin-Starry stain; ZN: Ziehl-Nielsen stain.

**Table 4 North-American – European divergences across oceans in gluten-sensitive enteropathy**


|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Target** | **Screening** | **PS-Tests 1** | **HLA-DQ** | **EMA** | **AGA** |
| ESPGHAN | Pediatric | Anti-tTG-IgA and IgA2 | Anti-tTG-IgG / Anti-DPG-IgG3 | Yes, if ↑EMA / anti-tTG | Yes, in confirming PS-tests | No |
| ACG | Pediatric  /Adult | Anti-tTG-IgA | Anti-tTG-IgG / Anti-DPG-IgG3 | Yes, if biopsy/serology disagreement | NS | No |
| WGO | NS | Anti-tTG-IgA / Anti-DPG IgG | NS | Yes, if biopsy/serology disagreement | Yes, in confirming PS-tests | No |

ESPGHA: European Society of Pediatric Gastroenterology, Hepatology, and Nutrition; ACG: American College of Gastroenterology; WGO: World Gastroenterology Organization; NS: Not specified.







**Figure 2 Intraepithelial lymphocytes and marsh classification.** A: Schema of the intraepithelial distribution of the intraepithelial lymphocytes (top, side, and down, see text); B: Marsh 0, normal villous architecture with en-face cut (H&E, × 100); C: Marsh I (H&E, × 100); D: Marsh IIIA (H&E, × 100); E: Marsh IIIB (H&E, × 100); and F: Marsh IIIC (H&E, × 100).



**Figure 3 Gluten-sensitive enteropathy mimickers.** A, B: Variable destructive patterns of Marsh IIIC of GSE (A: H&E, × 100; B: H&E, × 200); C, D: Eosinophilic duodenitis (H&E, × 400); E-F: Peptic duodenitis (H&E, × 400).



**Figure 4 Gluten-Sensitive Enteropathy Mimickers.** A: Lymphocytic gastritis with involvement of the duodenum (H&E, × 100); B: *H. pylori* gastritis (inset, Giemsa staining) (H&E and Giemsa × 630); C: Giardiasis (H&E, × 400); D: CMV infection (H&E, × 6300) and inset showing anti-CMV antibody reacting against viral proteins using an avidin-biotin complex immunoperoxidase immunohistochemical detection (× 100); E: Focal adenomatous change in duodenum (H&E, × 50); F: Sickle-cell-disease-related duodenitis (H&E, × 200).



**Figure 5 Gluten-sensitive enteropathy mimickers.** A-D: Post-Transplant Lympho-Proliferative Disorder, polymorphic type (A: H&E, × 50 and inset H&E, × 200) showing mononuclear epithelial and stromal infiltration with blasts and high CD20 (B, × 100) on CD3 (C, × 100) lymphocytes and high Epstein-Barr Virus replication (in situ hybridization or EBER, × 100); E: Burkitt lymphoma of the duodenum (H&E, × 100); and F: Tubular adenoma of the duodenum of a patient with familiar adenomatous polyposis (H&E, × 200).



**Figure 6 Synoptic report for gluten-sensitive enteropathy and gluten-sensitive enteropathy -mimickers**.